The Effect of Anti-Angiogenic Agents JFD and F16 on the Cell Cycle Arrest and Apoptosis Mechanisms in U87 and T98 Glioblastoma Cells
Abstract
Glioblastoma multiforme (GBM) is an aggressive type of cancer that can occur in the brain or spinal cord, with a 5-year survival rate of only 5%. Two novel anti-angiogenic agents, JFD and F16, have been developed and seem to be favorable for treating GBM. They work by inhibiting tumor angiogenesis, which is the formation of new blood vessels that plays a pivotal role in tumor growth. JFD is a small molecule that was developed for blocking vascular endothelial growth factor receptor (VEGFR). F16 is the second small molecule that can cross the blood brain barrier and block angiogenesis in tumors of the brain such as GBM. The aim of our research was to determine the cell cycle arrest and apoptosis ability of JFD original, JFD Water Soluble, F16, and F16 Analog on U87 and T98 glioblastoma cells using the western blot analysis method. After treating the cancer cells, the levels of APAF-1, Cleaved Caspase-3, PARP, p27 and p21 were analyzed. Our research hypothesized that these marker proteins would correlate with the cytotoxicity of glioblastoma cells. The western blot analysis showed that the expression of p27, PARP, and APAF-1 proteins are altered in T98 GBM cell lines following F16 and JFD treatments. These results require further verification in order to confirm the significance of the changes observed. (This research was supported by the generous funds provided by the Royal Dames of Cancer Research Inc., Ft. Lauderdale, Florida).
Faculty Sponsors
Dr. Appu Rathinavelu, Dr. Umamaheshwari Natarajan, Dr. Mir Saleem
Project Type
Event
Location
Alvin Sherman Library
Start Date
4-5-2023 12:00 PM
End Date
4-6-2023 4:00 PM
The Effect of Anti-Angiogenic Agents JFD and F16 on the Cell Cycle Arrest and Apoptosis Mechanisms in U87 and T98 Glioblastoma Cells
Alvin Sherman Library
Glioblastoma multiforme (GBM) is an aggressive type of cancer that can occur in the brain or spinal cord, with a 5-year survival rate of only 5%. Two novel anti-angiogenic agents, JFD and F16, have been developed and seem to be favorable for treating GBM. They work by inhibiting tumor angiogenesis, which is the formation of new blood vessels that plays a pivotal role in tumor growth. JFD is a small molecule that was developed for blocking vascular endothelial growth factor receptor (VEGFR). F16 is the second small molecule that can cross the blood brain barrier and block angiogenesis in tumors of the brain such as GBM. The aim of our research was to determine the cell cycle arrest and apoptosis ability of JFD original, JFD Water Soluble, F16, and F16 Analog on U87 and T98 glioblastoma cells using the western blot analysis method. After treating the cancer cells, the levels of APAF-1, Cleaved Caspase-3, PARP, p27 and p21 were analyzed. Our research hypothesized that these marker proteins would correlate with the cytotoxicity of glioblastoma cells. The western blot analysis showed that the expression of p27, PARP, and APAF-1 proteins are altered in T98 GBM cell lines following F16 and JFD treatments. These results require further verification in order to confirm the significance of the changes observed. (This research was supported by the generous funds provided by the Royal Dames of Cancer Research Inc., Ft. Lauderdale, Florida).
